NYSE:ORCL
NYSE:ORCLSoftware

Is Oracle (ORCL) Pricing Reflecting Its Cloud Ambitions Or Getting Ahead Of Itself

If you are wondering whether Oracle's current share price really lines up with its business fundamentals, you are not alone. That is exactly what this article will unpack for you. Oracle's stock last closed at US$202.29, with returns of 4.4% over 7 days, 6.5% over 30 days, 3.4% year to date, 30.7% over 1 year, 136.7% over 3 years and 253.4% over 5 years. This naturally raises questions about what a fair price might look like now. Recent news around Oracle has focused on its broader position...
NYSE:HCI
NYSE:HCIInsurance

Assessing HCI Group (HCI) Valuation Ahead Of Forecasted Major Earnings Growth

Why HCI Group (HCI) Is Back in Focus Ahead of Earnings HCI Group (HCI) is drawing attention after its share price slipped 1.87% in the latest session, as investors look ahead to an upcoming earnings report that is expected to show very large EPS growth versus last year. See our latest analysis for HCI Group. At a share price of US$176.06, HCI Group has had a mixed stretch recently, with a 1 month share price return of a 6.09% decline and a 3 month share price return of a 12.76% decline...
NasdaqGS:CNXN
NasdaqGS:CNXNElectronic

A Look At PC Connection (CNXN) Valuation After Weaker Quarterly Results And Market Pullback

PC Connection (CNXN) has been in focus after reporting quarterly revenue of US$709.1 million, a 2.2% year-on-year decline that missed analyst revenue and EPS estimates, with the stock down about 4% since the release. See our latest analysis for PC Connection. At a share price of US$58.78, the recent 4% pullback after the results comes on top of a 1-year total shareholder return decline of 15.38%. However, the 3-year and 5-year total shareholder returns of 20.17% and 20.41% present a more...
NYSE:BLK
NYSE:BLKCapital Markets

Assessing BlackRock (BLK) Valuation As Workforce Cuts Follow Strong Earnings And ETF And Alternatives Expansion

BlackRock (BLK) has drawn fresh attention after announcing a global workforce reduction of about 1% shortly after reporting stronger than expected quarterly earnings and reporting increased institutional flows into its exchange traded funds. See our latest analysis for BlackRock. BlackRock shares trade at US$1,089.54, with a 90 day share price return of a 9.4% decline but a 1 year total shareholder return of 15.44%. This suggests longer term holders have seen stronger gains even as recent...
NYSE:PBH
NYSE:PBHPharmaceuticals

A Look At Prestige Consumer Healthcare (PBH) Valuation After New TheraTears Eye Care Launch Plans

Prestige Consumer Healthcare (PBH) just moved to expand its TheraTears eye care line, announcing nationwide February 2026 launches for Eyelid Cleansing Wipes and Dry & Tired preservative free lubricant eye drops targeting screen related eye fatigue. See our latest analysis for Prestige Consumer Healthcare. The fresh TheraTears launches sit alongside a recent run of conference appearances and an upcoming fiscal 2026 third quarter earnings release. This is during a period where the share price...
NasdaqGS:OPEN
NasdaqGS:OPENReal Estate

A Look At Opendoor Technologies (OPEN) Valuation After Mortgage Bond Plan And Institutional Buying Ban Clarification

President Donald Trump’s proposal for a US$200b mortgage bond purchase plan, paired with assurances that Opendoor Technologies (OPEN) is not targeted by a potential institutional buying ban, sparked fresh interest in the iBuyer’s rate sensitive stock. See our latest analysis for Opendoor Technologies. Those policy headlines have come after an already eventful stretch for Opendoor, with recent mortgage bond proposals, leadership changes and the Homebuyer.com acquisition all feeding into a rate...
NasdaqGS:IDXX
NasdaqGS:IDXXMedical Equipment

A Look At IDEXX Laboratories (IDXX) Valuation Following Planned CEO Succession Announcement

IDEXX Laboratories (IDXX) has put a firm CEO succession plan in place, with Michael Erickson set to become President and Chief Executive Officer on May 12, 2026, as Jonathan Mazelsky moves to Executive Chair. See our latest analysis for IDEXX Laboratories. The CEO succession news comes after a strong run for long term holders, with the 1 year total shareholder return at 70.57% and the 5 year total shareholder return at 47.25%. The recent 90 day share price return of 11.72% suggests momentum...
NasdaqGS:DUOL
NasdaqGS:DUOLConsumer Services

Does Duolingo’s (DUOL) New CFO Appointment Reframe Its Trade-Off Between User Growth and Profit Focus?

Earlier in January 2026, Duolingo announced that long-time board member and Audit Chair Gillian Munson will become Chief Financial Officer on February 23, 2026, succeeding outgoing CFO Matt Skaruppa, who will shift to an advisory role to support a smooth transition. The company paired this leadership change with preliminary fourth-quarter 2025 figures showing strong year-over-year growth in daily active users and bookings, even as management emphasized ongoing product investment over...
NYSE:GEV
NYSE:GEVElectrical

Is It Too Late To Consider GE Vernova (GEV) After A 71% One-Year Rally?

If you are trying to figure out whether GE Vernova's current share price really makes sense, you are in the right place. The stock is up 71.0% over the last year, even though it has seen a 5.0% decline over the past week, a 2.9% decline over the past month and a 4.0% decline year to date from its last close of US$652.09. Recent news coverage has focused on GE Vernova's position in the capital goods space and how investors are responding to its role in the wider energy transition. This...
NYSE:RNR
NYSE:RNRInsurance

Is There Still Room In RenaissanceRe (RNR) After Strong Multi Year Share Price Gains?

If you are wondering whether RenaissanceRe Holdings is still good value at around US$270.10 per share, this breakdown is designed to help you make sense of the current price. The stock’s moves have been relatively muted recently, with a 0.7% decline over the last week, a 0.8% decline over the past month and year to date, and an 8.2% return over one year and 76.5% over five years. Recent attention on RenaissanceRe has centered on how the company is positioned within the insurance and...
NYSE:MRP
NYSE:MRPSpecialized REITs

3 Stocks Estimated To Be Trading At A Discount Of Up To 28.6%

As the U.S. stock market grapples with fluctuating bank earnings and inflation data, major indices like the Dow Jones, S&P 500, and Nasdaq have experienced recent declines. Amidst this volatility, identifying undervalued stocks can be a strategic move for investors looking to capitalize on potential market inefficiencies and secure assets at a discount.
NasdaqGM:BWMN
NasdaqGM:BWMNConstruction

Insiders Favor These 3 High Growth Stocks For Potential Gains

As the U.S. stock market navigates through a period marked by fluctuating bank earnings, inflation concerns, and record highs in precious metals, investors are keenly observing sectors that could offer potential growth amid these uncertainties. In such an environment, companies with high insider ownership often attract attention as they may indicate confidence from those who know the business best.
OTCPK:BUKS
OTCPK:BUKSAerospace & Defense

Clarus And 2 More Promising Penny Stocks

As major stock indexes in the United States face volatility due to recent bank earnings, inflation data, and fluctuating retail sales figures, investors are seeking alternative opportunities beyond traditional blue-chip stocks. Penny stocks, a term that might seem outdated but remains significant for many investors, often represent smaller or newer companies with potential for growth at lower price points. In this article, we explore three penny stocks that stand out for their financial...
NasdaqGS:TRST
NasdaqGS:TRSTBanks

Discovering US Undiscovered Gems in January 2026

As the U.S. market navigates through a period of fluctuating indices and economic indicators, small-cap stocks present unique opportunities amid broader market volatility. In this landscape, identifying promising companies requires a keen eye for innovation and resilience, particularly those that can thrive despite challenges such as inflationary pressures and shifting consumer trends.
NasdaqGS:PTCT
NasdaqGS:PTCTBiotechs

Does 2026 Revenue Guidance And Sephience Momentum Change The Bull Case For PTC Therapeutics (PTCT)?

In January 2026, PTC Therapeutics issued full-year 2026 guidance, projecting total product revenue of US$700 million to US$800 million, excluding Evrysdi royalty and collaboration revenue, while also reporting stronger-than-expected preliminary 2025 product and royalty results driven by Sephience. The company coupled its outlook with updates on regulatory and pipeline progress, including FDA alignment on a Phase 3 Huntington’s trial for votoplam and continued engagement on vatiquinone and...
NYSE:NRP
NYSE:NRPOil and Gas

Natural Resource Partners (NRP) Valuation Check After New 52 Week High And Solid Q3 2025 Earnings

Natural Resource Partners (NRP) recently set a new 52 week high at US$111.15 after releasing solid third quarter 2025 earnings. This has put fresh attention on how the partnership’s mineral and royalty profile is being valued. See our latest analysis for Natural Resource Partners. At the latest share price of US$114.20, NRP’s recent 1 month share price return of 9.42% and year to date share price return of 9.80% sit alongside a very large 5 year total shareholder return. This suggests...
NYSE:SXI
NYSE:SXIMachinery

Assessing Whether Standex International (SXI) Still Looks Undervalued After Sustained Shareholder Returns

Standex International (SXI) has quietly attracted fresh attention after recent share price gains, with the stock showing positive returns over the past month and over the past three months, prompting investors to reassess the diversified manufacturer. See our latest analysis for Standex International. At a latest share price of $241.82, Standex International has paired its recent short term gains with a 1 year total shareholder return of 33.08% and a 5 year total shareholder return of...
NasdaqGS:ILMN
NasdaqGS:ILMNLife Sciences

Illumina (ILMN) Valuation Check After Recent Share Price Rebound And Conflicting Fair Value Signals

Illumina (ILMN) is back on investors’ screens after recent trading, with the share price closing at US$146.99. The move comes against a backdrop of mixed short term returns and longer term share price pressure. See our latest analysis for Illumina. The recent 1 day share price return of 0.99% and 30 day share price return of 8.99% sit alongside a 90 day share price return of 58.05%. However, the 5 year total shareholder return of 61.24% and 3 year total shareholder return of 26.73% highlight...
NasdaqGS:TSEM
NasdaqGS:TSEMSemiconductor

Assessing Tower Semiconductor (NasdaqGS:TSEM) Valuation After New LiDAR And Silicon Photonics Partnership

Tower Semiconductor (NasdaqGS:TSEM) shares are in focus after the company and LightIC Technologies announced a collaboration on silicon photonics for frequency modulated continuous wave LiDAR in automotive, robotics, and Physical AI applications. See our latest analysis for Tower Semiconductor. The LightIC tie up comes after a stretch of strong momentum, with Tower Semiconductor’s share price at US$124.78 and a 90 day share price return of 68.24%, while the 1 year total shareholder return...
NYSE:ASH
NYSE:ASHChemicals

How Strengthening Analyst Consensus On Specialty Focus At Ashland (ASH) Has Changed Its Investment Story

In recent days, several brokerage firms have reiterated positive views on Ashland, with multiple analysts maintaining favorable ratings and expressing greater confidence in the company’s outlook. This broad alignment around an "Outperform" consensus signals that research houses are increasingly focusing on Ashland’s repositioned specialty chemicals profile and exposure to resilient end-markets. Against this backdrop of strengthening analyst consensus, we’ll examine how this renewed...
NYSE:BRC
NYSE:BRCCommercial Services

Brady (BRC) Valuation Check After Mixed Signals In Latest Results

Brady (BRC) is back in focus after its latest quarterly results highlighted a mix of strengths and questions, with long term revenue and EPS growth contrasted with slower organic growth in its core business. See our latest analysis for Brady. Those mixed signals seem to be reflected in the market, with the 90 day share price return of 9.33% and 1 year total shareholder return of 14.44% pointing to momentum that is still constructive rather than fading. If Brady’s latest results have you...
NYSE:DVA
NYSE:DVAHealthcare

Is DaVita’s (DVA) Community Health Push Reframing Its Role In Long-Term Care Management?

DaVita recently launched its Community Health Experience initiative, partnering with organizations such as the American Diabetes Association and the YMCA to deliver no-cost health screenings and education to under-resourced communities across the US. This program highlights how DaVita is tying kidney care to earlier detection of related conditions like diabetes and hypertension, potentially strengthening its role in broader community health management. Next, we’ll explore how this expanded...